¿Debemos utilizar balones liberadores de droga en pacientes con enfermedad de múltiples vasos?

Stentless Strategy in ACS: Perfusion and Drug Coated Balloons

The initial strategy for the treatment of patients at high risk of bleeding (HBR) after percutaneous coronary intervention (PCI) has consisted of a short dual antiaggregation therapy (DAPT). Stents continue to improve, which has allowed the reduction of DAPT schemes and therefore the incidence of bleeding.  However, researchers are also looking into another strategy to<a href="https://solaci.org/en/2023/11/22/stentless-strategy-in-acs-perfusion-and-drug-coated-balloons/" title="Read more" >...</a>

TCT 2023 | T-PASS TRIAL, ASA and Ticagrelor in Acute Coronary Syndrome

This is a multicenter randomized study including 2,850 patients with acute coronary syndrome. Patients were randomized to: dual antiplatelet therapy (DAPT) with ASA and ticagrelor during one month (1,426 patients), followed by ticagrelor monotherapy for 12 months, while the other group received DAPT with ASA and ticagrelor during 12 months (1,424 patients). This study was<a href="https://solaci.org/en/2023/10/30/tct-2023-t-pass-trial-asa-and-ticagrelor-in-acute-coronary-syndrome/" title="Read more" >...</a>

TCT 2023 | The WATCH-TAVR Study

In the TVT registry, around 40% of the patients eligible for transcatheter aortic valve replacement (TAVR) had atrial fibrillation, and there were high levels of adverse events after starting anticoagulant treatment, especially with oral anticoagulants (VKAs), primarily due to bleeding. The purpose of this study was to assess the feasibility, safety, and efficacy of combined<a href="https://solaci.org/en/2023/10/27/tct-2023-the-watch-tavr-study/" title="Read more" >...</a>

Resultados del estudio COMPARE a 2 años: Balones cubiertos de Paclitaxel con bajas dosis vs altas dosis

Ultrathin Stents Shown Safe and Effective in Real World Patients

Ultrathin drug eluting stents (60 µm) had been shown beneficial vs. thin-strut stents in terms of target lesion failure (TLF) at 2, 3 and 5 years in randomized studies, but they had not been yet assessed in “real world” patients.  The BIOFLOW VII is a prospective, multicenter study including 556 “real world”patients with a total<a href="https://solaci.org/en/2023/10/19/ultrathin-stents-shown-safe-and-effective-in-real-world-patients/" title="Read more" >...</a>

Left Main Coronary Artery PCI: In What Scenario Could We Not Use IVUS?

Lesions in the left main coronary artery (LMCA) continue to pose a significant challenge. The use of coronary imaging before percutaneous coronary implantation (PCI) has proven useful in analyzing the lesion, identifying the presence and location of calcification, and determining lesion length in the LMCA, the left anterior descending artery, and the circumflex artery. Various<a href="https://solaci.org/en/2023/10/10/left-main-coronary-artery-pci-in-what-scenario-could-we-not-use-ivus/" title="Read more" >...</a>

Transcatheter Closure of Patent Foramen Ovale in Thrombophilia Patients

The transcatheter treatment of patent foramen ovale (PFO) has been shown to reduce thromboembolic events in patients with cryptogenic stroke. However, most of large randomized studies have failed to include patients with thrombophilia, either inherited or acquired. For instance, the RESPECT study excluded patients with antiphospholipid antibodies (AFA) or hyperhomocysteinemia, while the REDUCE screened for<a href="https://solaci.org/en/2023/10/09/transcatheter-closure-of-patent-foramen-ovale-in-thrombophilia-patients/" title="Read more" >...</a>

POKI: una nueva estrategia en bifurcaciones

BIFURCAT Registry: 1 or 2 Stents? Treatment of Side Branch (Medina 0.0.1) Lesions According to Real-World Data

Coronary bifurcation lesions have been a subject to debate, with different approaches by various medical teams. These lesions often carry a higher risk of ischemic events compared with lesions at non-bifurcated sites. The main strategy, supported by medical society recommendations and clinical guidelines, involves using provisional stenting with one stent to minimize the number of<a href="https://solaci.org/en/2023/10/04/bifurcat-registry-1-or-2-stents-treatment-of-side-branch-medina-0-0-1-lesions-according-to-real-world-data/" title="Read more" >...</a>

Fentanilo en la angioplatia: ¿Cuál es el precio de un mayor confort en el procedimiento?

Substudy TALOS AMI: from Ticagrelor to Clopidogrel in Patients with High Risk of Bleeding and AMI

The preference for the use of potent P2Y12 inhibitors such as ticagrelor and prasugrel in patients with high risk of acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) is based on randomized studies and current guideline recommendations. However, clopidogrel is still recommended for patients at high risk of bleeding. Several strategies have been looked<a href="https://solaci.org/en/2023/09/20/substudy-talos-ami-from-ticagrelor-to-clopidogrel-in-patients-with-high-risk-of-bleeding-and-ami/" title="Read more" >...</a>

Diabetes y enfermedad vascular periférica: viejas drogas con nueva evidencia

BIFURCAT Registry: Long Term Diabetes Impact on Bifurcations PCI Outcomes

The impact of diabetes in patients with coronary artery disease (CAD) are well known, and after percutaneous coronary intervention (PCI), outcomes tend to be less favorable, with higher restenosis rate, repeat myocardial infarction (MI) and stent thrombosis. Despite the development of drug eluting stents, procedures and techniques, treating bifurcation lesions in diabetic patients still show<a href="https://solaci.org/en/2023/09/15/bifurcat-registry-long-term-diabetes-impact-on-bifurcations-pci-outcomes/" title="Read more" >...</a>

Relación entre calidad del vaso distal y resultados en tratamiento percutáneo de las oclusiones totales crónicas

What to Do in Cases of AMI with Multivessel Disease

The presence of lesions in multiple vessels is common in ST-segment elevation myocardial infarction (STEMI). It has been shown that, when they are treated in a second procedure, patients have a better outcome.  To date, there is limited information available on percutaneous transluminal coronary angioplasty (PTCA) in vessels with severe non-culprit lesions during primary angioplasty.<a href="https://solaci.org/en/2023/09/12/what-to-do-in-cases-of-ami-with-multivessel-disease/" title="Read more" >...</a>